Floatz logo

Durvalumab

Her2-Receptor Negative Breast Cancer

National Cancer Institute (NCI)monoclonal_antibodyPhase 3Active
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
89/ 100

Competitive context

185 Active assets in the Her2-Receptor Negative Breast Cancer cohort.

Asset / SponsorPhaseRating
Palbociclib
Helwan University
Phase 2BBB
Exemestane
National Cancer Institute (NCI)
Phase 4BBB
Pembrolizumab
UNC Lineberger Comprehensive Cancer Center
Phase 2BBB
Atezolizumab
TransThera Sciences (Nanjing), Inc.
Phase 2BB
Palazestrant
Olema Pharmaceuticals, Inc.
Phase 3BB

View all 50 →

Same molecule, other indications

Durvalumab is also rated in:

ovarian carcinomaActive
BB
Indicative · Phase 2
70 / 100
View asset →
primary peritoneal carcinomaActive
BB
Indicative · Phase 2
70 / 100
View asset →
urothelial carcinomaActive
BB
Indicative · Phase 3
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →